% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • bladerunner1717 bladerunner1717 May 17, 2013 5:38 AM Flag

    AZN offically announces taking Selumetinib into Phase III this year

    AstraZeneca Plc (AZN) will move three experimental cancer treatments into late-stage development as generic competition for its best-selling drugs intensifies.

    The U.K.’s second-biggest drugmaker is advancing development of moxetumomab pasudotox for hairy cell leukemia, olaparib for platinum-sensitive relapsed ovarian cancer and selumetinib for non-small cell lung cancer patients with the KRAS genetic mutation, the London-based company said today in a statement.
    Selumetinib, which the company licensed from Array Biopharma (ARRY), will begin testing in a late-stage trial in non-small cell lung cancer patients with a KRAS gene mutation during the second half of the year. AstraZeneca is also testing the treatment in melanoma patients with the same genetic mutation and for advanced pancreatic cancer


    Sentiment: Strong Buy

3.60+0.12(+3.45%)May 27 4:00 PMEDT